Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis

OBJECTIVE: To assess pooled golimumab safety up to year 3 of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) trials. METHODS: Golimumab 50 and 100 mg, administered subcutaneously (SC) every 4 weeks (q4wk), were assessed in patients with active RA (methotrexate-na...

Descripción completa

Detalles Bibliográficos
Autores principales: Kay, Jonathan, Fleischmann, Roy, Keystone, Edward, Hsia, Elizabeth C, Hsu, Benjamin, Mack, Michael, Goldstein, Neil, Braun, Jürgen, Kavanaugh, Arthur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345908/
https://www.ncbi.nlm.nih.gov/pubmed/24344160
http://dx.doi.org/10.1136/annrheumdis-2013-204195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345908/
https://www.ncbi.nlm.nih.gov/pubmed/24344160
http://dx.doi.org/10.1136/annrheumdis-2013-204195

Ejemplares similares